DePuy Synthes Secures Exclusive Distribution Rights for CGBIO's Growth Factor Bone Graft Substitute NOVOSIS
核心洞察
DePuy Synthes has entered an exclusive distribution agreement with CGBIO (搜索) for NOVOSIS, an advanced bone graft substitute containing growth factors (搜索), across the United States, Canada, and Australia.
NOVOSIS is designed to address unmet needs in orthopaedic care and is currently undergoing an FDA-approved investigational device exemption study for spine procedures.
The partnership expands DePuy Synthes' orthopaedic portfolio across spine, craniomaxillofacial, and trauma specialties with a differentiated regenerative medicine technology.
DePuy Synthes, a global leader in orthopaedic technologies and solutions, has announced an exclusive distribution agreement with CGBIO (搜索), a biotechnology company specializing in regenerative medicine, for the development and commercialization of NOVOSIS, an advanced bone graft substitute containing growth factors (搜索). The partnership covers the United States, Canada, and Australia, with DePuy Synthes also securing rights of first negotiation for additional global markets.
Novel Growth Factor Technology Addresses Clinical Gaps
NOVOSIS represents a novel approach to bone grafting, incorporating growth factors (搜索) designed to address unmet needs associated with existing solutions and support improved clinical outcomes. The technology will be integrated across DePuy Synthes' comprehensive orthopaedic portfolio, including spine, craniomaxillofacial (CMF), and trauma specialties.
"NOVOSIS has the potential to meaningfully advance orthopaedic care as a transformative treatment option for patients," said Namal Nawana, Worldwide President, DePuy Synthes. "This collaboration reflects our continued focus on strengthening our portfolio with differentiated technologies that address unmet needs and support patient care."
Clinical Development and Regulatory Progress
An investigational device exemption (IDE) study for spine procedures has been approved by the FDA and is actively enrolling patients in the United States to evaluate safety and effectiveness. If supported by clinical data and regulatory approval, NOVOSIS will expand treatment options within DePuy Synthes' spine portfolio.
The collaboration leverages the complementary strengths of both companies and builds upon the success of NOVOSIS in other international markets as the companies advance clinical development and prepare for future commercialization in key markets.
Expanding Global Footprint
This agreement represents the second major distribution partnership for NOVOSIS. Johnson & Johnson and CGBIO (搜索) previously entered into an exclusive distribution and promotional agreement for NOVOSIS in Korea, Taiwan, Thailand, India, Hong Kong, and Macau in February 2025, establishing a foundation for the technology's international expansion.
Strategic Portfolio Enhancement
The partnership strengthens DePuy Synthes' position in the regenerative medicine space, adding a differentiated bone graft substitute to complement its existing comprehensive orthopaedics portfolio. DePuy Synthes currently provides solutions across joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine, alongside the VELYS Digital Surgery portfolio.
The addition of NOVOSIS aligns with DePuy Synthes' strategy of advancing medical technologies and digital surgery across the continuum of care, building on the company's legacy of product innovation and industry firsts in shaping the orthopaedic landscape.